Trials / Completed
CompletedNCT03494270
High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients
A Randomized, Open, Parallel, Multicenter, Phase 4 Study to Compare High-intensity Rosuvastatin to Moderate-intensity Rosuvastatin/Ezetimibe in Atherosclerotic Cardiovascular Disease (ASCVD) Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 270 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of high-intensity rosuvastatin and moderate-intensity rosuvastatin/ezetimibe in ASCVD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvamibe | Rosuvastatin 10mg/Ezetimibe 10mg |
| DRUG | Monorova | Rosuvastatin 20mg |
Timeline
- Start date
- 2018-03-18
- Primary completion
- 2019-09-26
- Completion
- 2019-09-26
- First posted
- 2018-04-11
- Last updated
- 2019-12-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03494270. Inclusion in this directory is not an endorsement.